Immunitas Therapeutics, founded by Longwood Fund, employs a single cell genomics platform to dissect the biology of immune cells in human tumors, thereby advancing discoveries directly from the bench into meaningful clinical improvements. Our focus on human data allows us to start with and stay closer to the biology that is most relevant in patients and greatly accelerates the pace of our research. The Immunitas team of scientific pioneers innovates around each step of the drug development process, first identifying novel targets, then designing therapeutic strategies, and developing key biomarkers to guide the selection of patients who may benefit from our new drugs.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/21/19 | $39,000,000 | Series A |
Alexandria Venture Investments Evotec Leaps by Bayer  M Ventures Novartis Venture Funds | undisclosed |
| 08/18/21 | $58,000,000 | Series B |
120 Capital Agent Capital Alexandria Venture Investments BrightEdge Ventures Evotec Medical Excellence Capital Mirae Asset Venture Investment NS Investment Ono Venture Investment Solasta Ventures The Leukemia & Lymphoma Society The Mark Foundation for Cancer Research | undisclosed |
